• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Medtronic to put more skin into GI Dynamics through private placement

Medtronic to put more skin into GI Dynamics through private placement

August 5, 2011 By MassDevice staff

GI Dynamics

Medtronic Inc. (NYSE:MDT) is deepening its commitment to GI Dynamics Inc. by participating in a private placement concurrent with the Lexington, Mass.-based company’s initial public offering in Australia next week.

The Minneapolis, Minn.-based medical device giant, which has already invested $15 million in the company, has signaled its intention to be a part of a private placement of $19.7 million (AUS), about $20.7 million (USD), according to regulatory documents filed by GI Dynamics. Medtronic will join a number of the company’s existing shareholders in the private placement, by committing to another $5 million, which would make it the company’s largest corporate shareholder, besides venture capital firms.

Besides MDT, GI Dynamics has received investments from the Johnson & Johnson Development Corp., along with big venture capital firms Advanced Technology Ventures, Domain, Polaris Ventures and Cutlass Capital. All but JNJ are expected to participate in the private placement. About $6 million of the private placement will be convertible notes the company floated in the early summer under a bridge loan with current investors.

On Tuesday, GI Dynamics filed a prospectus with Australian regulators for an IPO that could fetch the firm between $80 to $95 million (AUS), which is about $86 million to $102 million (USD). The shares will not be issued until Aug. 11, 2011, according to the filing.

GI Dynamics’ move to file for an IPO in Australia before it has FDA approval in the U.S. is not without precedent. In 2005, Framingham, Mass.-based HeartWare International Inc. (NSDQ:HTWR) filed for an initial public offering on the ASX exchange, raising just over $32 million in the process. The company filed an IPO in the U.S. in 2007 and is traded on Nasdaq and the ASX.

EG Capital’s Howard Leibman told the Australian Lifescientist at the time of the filing that the Australian market made sense for companies still in the early stages of development.

“The US public markets have matured significantly so that in order to achieve a listing in the US you need commercial products — Phase III or beyond, or CE Mark or FDA approval,” Leibman said. “By comparison, the Australian market still has a greater appetite for earlier-stage medical device or biotechnology businesses, and as such provides potentially a valuable interim financing stage for a number of US companies.”

Read more of MassDevice.com’s coverage of GI Dynamics

GI Dynamics’ EndoBarrier gastrointestinal sleeve won Australian approval for treatment of type 2 diabetes and obesity just last week. The device won CE Mark in Dec., 2009, for six months of treatment, which prompted a $15 million investment from Medtronic Inc. (NYSE:MDT), which joined other investors in backing the firm as it prepared for commercial launch in the European Union.

The Endobarrier has since been approved for 12 months of treatment in the European Union, and is commercially available in Chile, Germany, the United Kingdom and the Netherlands. The company has also received an investigational device exemption approval to commence a pilot trial of the EndoBarrier in the U.S.

The EndoBarrier is a plastic sleeve inserted endoscopically into the small intestine, where it slows the uptake of nutrients from food to induce weight loss and help control the symptoms of diabetes.

The device can be implanted without surgery, which company president & CEO Stuart Randle views as the next wave for medical devices. "I think the next generation of technologies is going to be combinations of devices, combinations of drugs and combinations of devices and drugs, all focused on effecting multiple mechanisms of action simultaneously — and less invasively than surgery," Randle told MassDevice in a June 2009 interview.

A series of clinical studies in 2009, as well as more recent research, has showed that patients treated with the EndoBarrier reduced their average blood glucose levels and lowered other diabetic factors including fasting blood glucose, and morbidly obese patients lost significant amounts of weight.

Filed Under: News Well, Wall Street Beat Tagged With: Bariatrics, Gastrointestinal, GI Dynamics

More recent news

  • A new way to monitor glucose: Glucotrack explains 3-year CBGM implant technology
  • Dexcom continues advances in AI for CGM, type 2 diabetes awareness
  • Tandem continues to deliver more options, benefits for those with diabetes
  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy